Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

about

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.Engineering multi-specific antibodies against HIV-1

P2860

Q47174470-85F8DAD1-DD9C-4ED9-8E55-C8752B738042 Q58696428-8BBDD2D5-D769-4BC4-BA46-75DB9982B19E

P2860

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

Item

http://www.wikidata.org/entity/Q39238361

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

@en

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

@nl

type

Item

label

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

@en

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

@nl

prefLabel

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

@en

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

@nl

P1476

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

@en

P2093

Amos Wu

http://www.w3.org/2001/XMLSchema#string

Chasity D Andrews

http://www.w3.org/2001/XMLSchema#string

Craig Pace

http://www.w3.org/2001/XMLSchema#string

David D Ho

http://www.w3.org/2001/XMLSchema#string

Michael S Seaman

http://www.w3.org/2001/XMLSchema#string

Ming Sun

http://www.w3.org/2001/XMLSchema#string

Neal N Padte

http://www.w3.org/2001/XMLSchema#string

Qing Fang

http://www.w3.org/2001/XMLSchema#string

Ruijiang Song

http://www.w3.org/2001/XMLSchema#string

P2860

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults

Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

P304

365-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0000000000001119

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27792681

http://www.w3.org/2001/XMLSchema#string

P932

5123706

http://www.w3.org/2001/XMLSchema#string

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

about

P2860

P2860

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932